SCHEMBL640579

SCHEMBL640579

CCOC(=O)C(c1ccccc1)n1c(=O)n(C(=O)O)c2ccc(I)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.36
LMNA P02545 5/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
MDM2 Q00987 2/20 0.35
HSD17B10 Q99714 2/20 0.35
MDM4 O15151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TSHR P16473 2/20 0.34
GAA P10253 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRB2 P47870 2/20 0.34
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641508 0.86 GABRG2 (0.35) LMNAALDH1A1MAPTMDM2NPSR1
SCHEMBL639801 0.84 LMNA (0.42) MMP8LMNAALDH1A1MAPTMDM2
SCHEMBL639976 0.76 LMNA (0.60) LMNAALDH1A1MAPTHSD17B10NPSR1
SCHEMBL641167 0.75 L3MBTL1 (0.48) LMNAALDH1A1MAPTMDM2NPSR1
SCHEMBL640561 0.72 LMNA (0.42) MMP8LMNAALDH1A1MAPTMDM2
SCHEMBL639642 0.70 MEN1 (0.46) LMNAALDH1A1MAPTNPSR1MEN1
SCHEMBL639733 0.66 MDM2 (0.44) LMNAALDH1A1MAPTMDM2NPSR1
SCHEMBL10840334 0.65 MMP8 (0.50) MMP8LMNAALDH1A1MAPTMDM2
SCHEMBL642618 0.65 LMNA (0.41) LMNAALDH1A1MDM2MEN1KMT2A
SCHEMBL15700139 0.65 ALDH1A1 (0.47) MMP8LMNAALDH1A1HSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MMP8 1803/4885LMNA 886/4885ALDH1A1 586/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MMP8 1803/4885LMNA 886/4885ALDH1A1 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.